NCT05111210Recruiting
Exploration of the Cellular and Molecular Mechanisms in Patients Receiving Biotherapies Targeting the IL-23/IL-17 Axis in Cutaneous Psoriasis
Source: ClinicalTrials.gov · Last updated 14 May 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This is a research study involving humans, of the interventional type with minimal risks and constraints (RIPH2). It is a monocentric, non randomized prospective study aiming to better understand the mechanisms of the response to anti-IL-23 biologics in psoriasis patients attending the dermatology department of hospital Cochin (APHP).
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 90 (estimated)
- First submitted
- 27 Oct 2021
- Start date
- 14 Dec 2021
- Primary completion date
- 30 Jun 2028
- Lead sponsor
- Institut Pasteur
- Diseases
- Psoriasis
- NCT number
- NCT05111210
What you commit to
- Study type: Observational
- Planned participants: 90
- From 14 Dec 2021 to the primary completion date, 30 Jun 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Who the study is looking for
- All patients:
- Adults (\>18 years)
- Presenting with cutaneous psoriasis
- Patients have signed an informed consent
- Beneficiary of the health insurance, except for the AME Only for patients of Group 1
- Patients require systemic treatment for psoriasis
- Patients are naïve to biological therapies
- Only for patients of Group 2:
- Patients requiring treatment with anti-IL-23 biologics (guselkumab, risankizumab, tildrakizumab) upon referent physician's decision.
- Patients are naïve to biological therapies or have received only one biologic, with a "wash-out" period of at least 4 months
- Non inclusion Criteria:
- For all :
- Patient is minor
- Patient is pregnant or breastfeeding
- Patient is immunocompromised
- Patient is under legal protection, curatorship, guardianship
- Patient refuses consent
- Patient is unable to comply with study requirements for geographic, social or psychiatric reason.
- Beneficiary of the AME Only for patients of Group 1
- Patient has received biologics Only for patients of Group 2
- Patient has a contraindication to the chosen biotherapy
- Patient has received biologics within the last 4 months
- Patient has been treated with 2 or more biologics
- Patient has already received an anti-IL-23 biologic
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Lars ROGGE Coordinator of this site? Confirm its status | Paris | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.